title: M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) and bladder preservation.
authors.affiliation: Oncology Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, N.Y.
authors.forename: H
authors.initials: H
authors.lastname: Scher
authors.forename: H
authors.initials: H
authors.lastname: Herr
authors.forename: C
authors.initials: C
authors.lastname: Sternberg
authors.forename: W
authors.initials: W
authors.lastname: Fair
authors.forename: G
authors.initials: G
authors.lastname: Bosl
authors.forename: M
authors.initials: M
authors.lastname: Morse
authors.forename: P
authors.initials: P
authors.lastname: Sogani
authors.forename: R
authors.initials: R
authors.lastname: Watson
authors.forename: D
authors.initials: D
authors.lastname: Darshaw
authors.forename: V
authors.initials: V
authors.lastname: Reuter
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009132:Muscles / Q000473:pathology; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D015996:Survival Rate; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D014747:Vinblastine; D004317:Doxorubicin; D002945:Cisplatin; D008727:Methotrexate